IS INFLAMMATION AN AGE-RELATED CAUSE OF BPH PROGRESSION

##plugins.themes.bootstrap3.article.main##

##plugins.themes.bootstrap3.article.sidebar##

PDF
Published 2011-01-01
Hendra Herman Agus Rizal AH Hamid Chaidir Arif Mochtar

Abstract

Objective: To find the role of inflammation in BPH progression represented by prostate enlargement compared between age group. Material & method: Tissue samples of BPH were collected from biopsy, transurethral resection or open surgery. Clinical information was collected including such as patient age, prostate volume, serum prostate specific antigen (PSA) and history of retention before procedure. Patients were divided into three groups, below 63 years old (young adult), 63 - 69 years old (older adult) and equal or above 70 years old (elderly). The samples were analyzed to define the microscopic structure of the hyperplasia (stromal or glandular) and to detect prostatic intraepithelial neoplasia, atypical stromal acinic proliferation, atypical acinar hyperplasia or prostate cancer. Prostate cancer was excluded from study samples. Grade of inflammation was determined by a pathologist depending on number of inflammatory cells. Grade of inflammation was classified in two groups, with mild inflammation or moderate-to-severe inflammation. Results: A total of 1189 patients were reviewed, 1172 were diagnosed with BPH. There were 381 patients (32,5%) with age below 63 years old (young adult), 380 (32,4%) between 63-69 years old (older adult) and 411 (35,1%) in equal or above 70 years old (elderly). In young-adult group, median of prostate volume between mild and moderate to severe inflammations was 42,56 and 45,75 (p = 0,500), for older adult group median was 45,00 and 51,00 (p = 0,038), for elderly group median was 49,00 and 51,98 (p = 0,621). Conclusion: Inflammation has a role in progression of prostate enlargement especially for the older adult group. Keywords: inflammation in BPH progression, prostate volume, age, PSA.


##plugins.themes.bootstrap3.article.details##

References

Stern JA, Fitzpatrick JM, Mc Vary KT. Prostate anatomy and causative theories, pathophysiology, and natural history of benign prostatic hyperplasia, In: Management of benign prostatic hyperplasia. Humana Press Inc; 2004. p. 1–19.

Flanigan RC, Reda DJ, Wasson JH. 5-year outcome of surgical resection and watchful waiting for men with moderately symptomatic BPH. A Department of Veterans Affairs Cooperative Study. J Urol 1998; 160: 12–5.

Kessler JO, Keisari Y, Servadio C. Role of chronic inflammation in the promotion of prostatic hyperplasia in rats. J Urol 1998; 159: 1049–53.

Nickel JC. Inflammation and benign prostatic hyperplasia. Urol Clin N Am 2007; 35: 109–15.

Blotnick S, Peoples G, Freeman MR. T-lymphocytes synthesize and export heparin-binding epidermal growth factor-like growth factor and basic fibroblast growth factor, mitogens for vascular cells and fibroblasts: Differential production and release by CD4+ and CD8+T cells. Proc Natl Acad Sci USA 1994; 91: 2890–4.

Konig JE, Senge T, Allhoff EP. Analysis of the inflammatory network in benign prostate hyperplasia and prostate cancer. Prostate 2004; 58: 121–9.

Kramer G, Steiner GE, Handisurya A. Increased expression of lymphocyte-derived cytokines in benign hyperplastic prostate tissue, identification of the producing cell types, and effect of differentially expressed cytokines on stromal cell proliferation. Prostate 2002; 52: 43–58.

Steiner GE, Newman ME, Paikl D. Expression and function of pro-inflammatory interleukin IL-17 and IL-17 receptor in normal, benign hyperplastic, and malignant prostate. Prostate 2003; 56: 171–82.

Castro P, Xia C, Gomez L. Interleukin-8 expression is increased in senescent prostatic epithelial cells and promotes the development of benign prostatic hyperplasia. Prostate 2004; 60: 153–9.

Kakehi Y, Segawa T, Wu XX. Down-regulation of macrophage inhibitory cytokine-1/prostate derived factor in benign prostatic hyperplasia. Prostate 2004; 59: 351–6.

Taoka R, Tsukuda F, Ishikawa M. Association of prostatic inflammation with down-regulation of macrophage inhibitory cytokine-1 gene in symptomatic benign prostatic hyperplasia. J Urol 2004; 171: 2330–5.

Wang W, Bergh A, Damber JE. Chronic inflammation in benign prostate hyperplasia is associated with focal upregulation of cyclooxygenase-2, Bcl-2, and cell proliferation in the glandular epithelium. Prostate 2004; 61: 60–72.

Theyer G, Kramer G, Assmann I. Phenotypic characterization of infiltrating leukocytes in benign prostatic hyperplasia. Lab Invest 1992; 66: 96-107.

Freeman M, Schneck F, Gagnon ML. Peripheral blood T lymphocytes and T cells infiltrating human cancers express vascular endothelial growth factor: Potential role for T cells in angiogenesis. Cancer Res 1995; 55: 4140–5.

Delongchamps NB, De la Roza G, Chandan V. Evaluation of prostatitis in autopsied prostates – is chronic inflammation more associated with benign prostatic hyperplasia or cancer? J Urol 2008; 179: 1736–40.

Sciarra A, Di Silverio F, Salciccia S. Inflammation and chronic prostatic diseases: Evidence for a link? Eur Urol 2007; 52: 964–72.

Nickel JC, Roehrborn CG, O’Leary MP. Examination of the relationship between symptoms of prostatitis and histological inflammation. Baseline data from the REDUCE chemoprevention trial. J Urol 2007, 178: 896–901.

Bosch JL, Hop WC, Kirkels WJ, Schröder FH. Natural history of benign prostatic hyperplasia: Appropriate case definition and estimation of its prevalence in the community. Urology 1995; 46: 34–40.

Wang L, Yang JR, Yang LY. Chronic inflammation in benign prostatic hyperplasia: Implications for therapy. Medical Hypotheses 2008; 70: 1021–3.

Yousfi M, Mercier S, Breuillé D. The inflammatory response to vaccination is altered in the elderly. Mech of Ageing and Dev 2005; 126: 874–81.

Licastro F, Candore G, Lio D. Innate immunity and inflammation in ageing: A key for understanding age-related diseases, licensee Ltd Bio Med Central © 2005 was downloading from http://www.immunityageing.com/content/2/1/8.

Delongchamps NB, De la Roza G, Chandan V. Evaluation of prostatitis in autopsied prostates – is chronic inflammation more associated with benign prostatic hyperplasia or cancer? J Urol 2008; 179: 1736–40.

Novara G, Galfano A, Berto RB. Inflammation, apoptosis, and BPH: What is the Evidence? Eur Urol 2006; 5: 401–9.

Hamid AR, Mochtar CA, Umbas R, Budiana. The role of inflammation on BPH progression: Study on PSA and prostate volume: Unpublished data; 2008.

Navarrete RV, Garcia Cardoso JV, Barat A. BPH and inflammation: Pharmacological effects of permixon on histological and molecular inflammatory markers. Results of a double blind pilot clinical assay. Eur Urol 2003; 44: 549–55.

St. Sauver JL, Jacobson DJ, McGree ME. Protective association between nonsteroidal anti inflammatory drug use and measures of benign prostatic hyperplasia. Am J Epidemiol 2006; 164: 497–504.

Section
January 2011 Vol. 18 No. 1
Copyright Information
Department of Urology, Faculty of Medicine/Airlangga University